Acotec Scientific Holdings Limited (HK:6669)
:6669
Top Page
Acotec Scientific Holdings Limited
(6669)
Select Model
Select Model
Rating:67Neutral
Price Target:
HK$15.00
▲(5.93% Upside)
Action:ReiteratedDate:11/21/25
Acotec Scientific Holdings Limited shows strong financial performance with robust revenue growth and cash flow metrics, which are the most significant factors supporting its stock score. However, the technical indicators suggest neutral market sentiment, and the high P/E ratio indicates potential overvaluation, which slightly dampens the overall score.
Positive Factors
High gross margins
A 75.23% gross margin signals strong product-level profitability and likely differentiated, high-value consumables in vascular intervention. Durable margin strength supports reinvestment in R&D and manufacturing scale, providing pricing flexibility and competitive cushioning over time.
Negative Factors
Modest net profit margin
A 17.02% net margin, while positive, lags the firm’s very high gross margin and implies significant operating costs or lower operating leverage. Unless SG&A and other expenses are controlled, net margin compression could limit retained earnings and long-term return generation for shareholders.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
A 75.23% gross margin signals strong product-level profitability and likely differentiated, high-value consumables in vascular intervention. Durable margin strength supports reinvestment in R&D and manufacturing scale, providing pricing flexibility and competitive cushioning over time.
Read all positive factors
Acotec Scientific Holdings Limited (6669) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$4.01B
Dividend YieldN/A
Average Volume (3M)462.19K
Price to Earnings (P/E)31.5
Beta (1Y)0.91
Revenue Growth12.94%
EPS Growth212.66%
CountryHK
Employees650
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.11
Shares Outstanding313,389,160
10 Day Avg. Volume400,669
30 Day Avg. Volume462,190
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.25
Price to Sales (P/S)3.16
P/FCF Ratio317.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$17.00Price Target Upside20.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.5
Revenue Forecast (FY)HK$849.61M
Acotec Scientific Holdings Limited Business Overview & Revenue Model
Company Description
Acotec Scientific Holdings Limited, a medical device company, researches and develops percutaneous transluminal angioplasty and drug-coated balloon products for the treatment of vascular diseases in Mailand China, Europe, and internationally. It o...
How the Company Makes Money
Acotec Scientific Holdings Limited generates revenue primarily through the sale of its medical devices, which are marketed to hospitals and healthcare providers. The company employs a business-to-business (B2B) revenue model, where it sells its pr...
Acotec Scientific Holdings Limited Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
70
Positive
Cash Flow
80
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 592.85M | 533.99M | 473.85M | 395.55M | 303.81M | 193.97M |
| Gross Profit | 446.01M | 402.72M | 377.42M | 336.35M | 265.94M | 163.78M |
| EBITDA | 81.08M | 112.48M | 70.54M | 91.17M | -51.02M | -24.66M |
| Net Income | 100.90M | 52.28M | 14.49M | 70.14M | -79.08M | -43.84M |
Balance Sheet | ||||||
| Total Assets | 1.83B | 1.66B | 1.61B | 1.41B | 1.31B | 272.94M |
| Cash, Cash Equivalents and Short-Term Investments | 995.38M | 809.57M | 879.21M | 986.46M | 1.14B | 147.10M |
| Total Debt | 236.13M | 202.92M | 234.00M | 47.78M | 24.57M | 41.41M |
| Total Liabilities | 384.00M | 312.76M | 314.53M | 134.46M | 100.17M | 553.95M |
| Stockholders Equity | 1.44B | 1.35B | 1.30B | 1.28B | 1.21B | -281.01M |
Cash Flow | ||||||
| Free Cash Flow | 159.00M | 5.31M | -92.54M | -115.45M | -31.72M | -27.39M |
| Operating Cash Flow | 194.51M | 102.79M | -12.88M | -68.75M | -10.48M | -8.77M |
| Investing Cash Flow | -203.20M | 45.02M | -319.22M | -49.17M | -20.48M | -17.73M |
| Financing Cash Flow | -35.32M | -35.24M | -23.21M | -32.87M | 1.02B | 142.52M |
Acotec Scientific Holdings Limited Technical Analysis
Positive
14.16
Price Trends
12.91
Negative
13.06
Negative
12.48
Positive
Market Momentum
0.07
Negative
54.77
Neutral
87.11
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6669, the sentiment is Positive. The current price of 14.16 is above the 20-day moving average (MA) of 12.03, above the 50-day MA of 12.91, and above the 200-day MA of 12.48, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 54.77 is Neutral, neither overbought nor oversold. The STOCH value of 87.11 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6669.
Acotec Scientific Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | HK$4.01B | 31.51 | 7.22% | ― | 12.94% | 212.66% | |
61 Neutral | HK$2.12B | 22.44 | 4.25% | ― | 32.93% | ― | |
53 Neutral | HK$961.41M | -1.91 | -30.05% | ― | -8.56% | -14.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$4.24B | -18.13 | -11.27% | ― | 29.25% | 9.02% | |
44 Neutral | HK$3.15B | -495.98 | -1.35% | ― | 49.86% | 80.35% | |
43 Neutral | HK$3.78B | -218.71 | 0.22% | ― | -4.38% | ― |
* Healthcare Sector Average
HK:6669
Acotec Scientific Holdings Limited
12.79
6.09
90.90%
HK:9996
Peijia Medical Ltd.
6.32
1.95
44.62%
HK:2160
MicroPort CardioFlow Medtech Corp.
2.97
-0.98
-24.81%
HK:2235
MicroTech Medical (Hangzhou) Co., Ltd. Class H
7.48
1.57
26.57%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
2.18
0.13
6.34%
HK:6609
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
54.50
27.50
101.85%
Acotec Scientific Holdings Limited Corporate Events
Acotec Shareholders Approve 2026 Collaboration Framework With Controlling Shareholder BSG
Dec 31, 2025
Acotec Scientific Holdings Limited announced that all resolutions proposed at its extraordinary general meeting held in Beijing on 31 December 2025 were duly passed by shareholders through poll voting. Independent shareholders representing about 6...
Acotec Scientific to Hold EGM for Key Agreement Approvals
Dec 16, 2025
Acotec Scientific Holdings Limited has announced an extraordinary general meeting scheduled for December 31, 2025, to approve and ratify two significant agreements with BSG. These agreements, the 2026 Master Collaboration Agreement and the 2026 Ma...
Acotec Extends Strategic Collaboration with Boston Scientific Group
Dec 12, 2025
Acotec Scientific Holdings Limited has entered into two significant agreements with its controlling shareholder, Boston Scientific Group Limited (BSG), to extend their collaboration and service arrangements for another three years, from January 1,...
Acotec Scientific Announces EGM and Closure of Register of Members
Dec 10, 2025
Acotec Scientific Holdings Limited has announced the closure of its register of members in preparation for an extraordinary general meeting (EGM) scheduled for December 31, 2025. This closure, from December 24 to December 31, 2025, is to determine...
Acotec Scientific Secures Approval for Microcatheter V-otter
Dec 3, 2025
Acotec Scientific Holdings Limited announced that it has received registration approval from the PRC National Medical Products Administration for its new product, the Microcatheter V-otter. This microcatheter is designed for Transarterial Chemoemb...
Acotec Scientific Gains Approval for New Cardiovascular Device
Nov 18, 2025
Acotec Scientific Holdings Limited announced that it has received approval from the PRC National Medical Products Administration for its Coronary Over-the-Wire Balloon Dilatation Catheter Jingyi. This product is designed to improve myocardial perf...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.